My view is that : Natco Pharma looks all set to run from here:
- EPS of 70+ is sure for FY 24 and even taking a moderate 25 PE valuation make it reach Rs 1750 in short term.
- Cash surplus of 1800 Cr.
- With its developments in Oncology segment, next 2-3 years look really good for growth.
| Subscribe To Our Free Newsletter |
